Parkman Healthcare Partners LLC Purchases Shares of 412,888 AxoGen, Inc. (NASDAQ:AXGN)

Parkman Healthcare Partners LLC acquired a new position in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 412,888 shares of the medical equipment provider's stock, valued at approximately $5,789,000. Parkman Healthcare Partners LLC owned about 0.94% of AxoGen at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its holdings in shares of AxoGen by 8.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider's stock worth $240,000 after acquiring an additional 2,204 shares during the last quarter. Assenagon Asset Management S.A. raised its position in AxoGen by 2,014.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,310,811 shares of the medical equipment provider's stock valued at $9,490,000 after buying an additional 1,248,823 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of AxoGen by 9.4% in the second quarter. Bank of New York Mellon Corp now owns 160,892 shares of the medical equipment provider's stock valued at $1,165,000 after purchasing an additional 13,798 shares during the last quarter. Rhumbline Advisers lifted its position in shares of AxoGen by 6.2% during the 2nd quarter. Rhumbline Advisers now owns 58,157 shares of the medical equipment provider's stock worth $421,000 after buying an additional 3,380 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of AxoGen in the 2nd quarter worth approximately $125,000. Institutional investors and hedge funds own 80.29% of the company's stock.

AxoGen Price Performance

Shares of AxoGen stock traded up $0.39 during trading on Wednesday, hitting $14.83. The stock had a trading volume of 162,636 shares, compared to its average volume of 397,030. The firm has a market cap of $652.64 million, a price-to-earnings ratio of -45.13 and a beta of 1.06. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. The business's 50-day moving average is $13.70 and its 200 day moving average is $11.03. AxoGen, Inc. has a 12 month low of $5.55 and a 12 month high of $15.90.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. StockNews.com raised AxoGen from a "hold" rating to a "buy" rating in a research report on Tuesday, October 15th. JMP Securities boosted their target price on shares of AxoGen from $17.00 to $20.00 and gave the company a "market outperform" rating in a research note on Friday, August 9th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $15.00.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.